Peptide · Growth-hormone-releasing hormone (GHRH) analogue
Tesamorelin
A synthetic analogue of growth-hormone-releasing hormone, authorised for one narrow use: reducing excess abdominal fat in people with HIV-associated lipodystrophy.
Approved medicineAuthorised by a regulator, available on prescription.
- Legal status · US
- Approved medicine
- Evidence in people
- Molecule
- 44 amino acids
- In sport
- Prohibited (WADA)
- Status checked
Regulatory status · United States
This describes the position in the United States. Rules in European Union differ; an approved peptide medicine there is in its national register.
An approved prescription medicine for that single indication. Use for anything else is off-label and is not what the approval covers.
Growth-hormone-releasing factors are prohibited at all times under WADA class S2.
Authorised products
| Brand | Authorised for | How it is given | First US approval |
|---|---|---|---|
| Egrifta | Abdominal fat in HIV-associated lipodystrophy | Injection, once a day | 2010 |
Doses, warnings and who should not use it are on each product’s official label, linked from its page.
Every authorised product in European UnionWhat changed, and when
US approval, as Egrifta, for HIV-associated lipodystrophy.
What to be careful about
Sold online alongside research peptides as a "GH booster". The approval covers one population and one use; it says nothing about body composition in anyone else.
Sources
Regulatory positions change. This page states the date it describes, and nothing on it is legal or medical advice.